CH630804A5 - Verfahren zur verhinderung des abbaus der biochemischen aktivitaet von antihaemophilie-globulin. - Google Patents

Verfahren zur verhinderung des abbaus der biochemischen aktivitaet von antihaemophilie-globulin. Download PDF

Info

Publication number
CH630804A5
CH630804A5 CH700173A CH700173A CH630804A5 CH 630804 A5 CH630804 A5 CH 630804A5 CH 700173 A CH700173 A CH 700173A CH 700173 A CH700173 A CH 700173A CH 630804 A5 CH630804 A5 CH 630804A5
Authority
CH
Switzerland
Prior art keywords
heparin
ahg
globulin
plasma
glycine
Prior art date
Application number
CH700173A
Other languages
German (de)
English (en)
Inventor
Lajos F Fekete
Stephen L Holst
Original Assignee
Baxter Travenol Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Lab filed Critical Baxter Travenol Lab
Publication of CH630804A5 publication Critical patent/CH630804A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Golf Clubs (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Medicinal Preparation (AREA)
CH700173A 1972-05-17 1973-05-16 Verfahren zur verhinderung des abbaus der biochemischen aktivitaet von antihaemophilie-globulin. CH630804A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00254148A US3803115A (en) 1972-05-17 1972-05-17 Stabilization of ahf using heparin

Publications (1)

Publication Number Publication Date
CH630804A5 true CH630804A5 (de) 1982-07-15

Family

ID=22963114

Family Applications (1)

Application Number Title Priority Date Filing Date
CH700173A CH630804A5 (de) 1972-05-17 1973-05-16 Verfahren zur verhinderung des abbaus der biochemischen aktivitaet von antihaemophilie-globulin.

Country Status (18)

Country Link
US (2) US3803115A (ja)
JP (1) JPS596845B2 (ja)
AT (1) AT344881B (ja)
AU (1) AU465351B2 (ja)
BE (1) BE799525A (ja)
CA (1) CA1007986A (ja)
CH (1) CH630804A5 (ja)
DE (1) DE2324717C3 (ja)
DK (1) DK136016B (ja)
ES (1) ES414823A1 (ja)
FR (1) FR2184898B1 (ja)
GB (1) GB1372515A (ja)
IL (1) IL42221A (ja)
IT (1) IT1061433B (ja)
NL (1) NL7306806A (ja)
NO (1) NO142381C (ja)
SE (1) SE430020B (ja)
ZA (1) ZA733138B (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
US4022758A (en) * 1973-06-19 1977-05-10 Ab Kabi Isolation of coagulation factors I and VIII from biological material
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4089944A (en) 1975-12-22 1978-05-16 Baxter Travenol Laboratories, Inc. Rapidly solubilized AHF composition and process for preparing same
JPS52125609A (en) * 1976-04-09 1977-10-21 Green Cross Corp:The Purification of agglutination factor viii
DE2624373C2 (de) * 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
CA1074698A (en) * 1977-12-19 1980-04-01 Gail A. Rock Method of collecting anti-hemophilic factor viii from blood and blood plasma
AT359646B (de) * 1979-04-19 1980-11-25 Immuno Ag Verfahren zur herstellung von nebenwirkungs- freien plasmafraktionen
US4210580A (en) * 1979-06-19 1980-07-01 David Amrani Process for separation and isolation of AHF and fibronectin from blood plasma
US4278594A (en) * 1979-06-19 1981-07-14 David Amrani Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma
US4289691A (en) * 1980-01-18 1981-09-15 The Canadian Red Cross Society Method of obtaining intermediate purity factor VIII
EP0033582B1 (en) * 1980-01-18 1984-04-11 The Canadian Red Cross Society Method of obtaining factor viii
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
CA1178887A (en) * 1981-10-01 1984-12-04 Gail A. Rock Factor viii concentrates prepared from heparinized plasma by the application of a cold precipitation technique
US4397841A (en) 1982-06-28 1983-08-09 Monsanto Company Production of blood coagulation factor VIII:C
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
GB8505882D0 (en) * 1985-03-07 1985-04-11 Central Blood Lab Authority Purification of blood coagulation factor viii
EP0238701B1 (de) * 1986-03-27 1992-03-18 Octapharma AG Verfahren zur Herstellung eines hochgereinigten Antihämophilie-Faktors
USH1509H (en) * 1989-06-09 1995-12-05 Eran; Harutyun Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
FR2657884B1 (fr) * 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US8389687B2 (en) * 2000-10-23 2013-03-05 Shanbrom Technologies, Llc Polyvinylpyrrolidone cryoprecipitate extraction of clotting factors
US6881731B1 (en) * 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
US7411006B2 (en) * 2000-10-23 2008-08-12 Shanbrom Technologies, Llc Enhanced production of blood clotting factors and fibrin fabric
US7297716B2 (en) * 2000-10-23 2007-11-20 Shanbrom Technologies, Llc Enhanced production of blood components, blood cells and plasma without freezing
CA2438223A1 (en) * 2001-02-07 2002-11-07 Shanbrom Technologies, Llc Carboxylic acid such as citric acid for desinfecting or enhacing the production of blood products such as plasma, cryoprecipitate or/and platelet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867567A (en) * 1955-01-21 1959-01-06 Nat Res Dev Process of preparing anti-haemophilic globulin
DE1949314U (de) 1966-05-07 1966-11-10 Braun Fa B Bohrdraht-bereitschaftskasten.
BE713764A (ja) 1967-05-01 1968-09-16 Baxter Travenol Lab
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3560475A (en) * 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol

Also Published As

Publication number Publication date
IL42221A0 (en) 1973-07-30
DE2324717A1 (de) 1973-12-13
ATA433573A (de) 1975-04-15
DK136016B (da) 1977-08-01
FR2184898B1 (ja) 1976-11-05
GB1372515A (en) 1974-10-30
SE430020B (sv) 1983-10-17
JPS4956695A (ja) 1974-06-01
DE2324717B2 (de) 1980-01-03
USRE29698E (en) 1978-07-11
ES414823A1 (es) 1976-02-01
JPS596845B2 (ja) 1984-02-15
IT1061433B (it) 1983-02-28
BE799525A (fr) 1973-08-31
AU5584973A (en) 1974-11-21
IL42221A (en) 1977-04-29
DE2324717C3 (de) 1983-12-01
FR2184898A1 (ja) 1973-12-28
AU465351B2 (en) 1975-09-25
ZA733138B (en) 1974-03-27
NO142381C (no) 1980-08-13
CA1007986A (en) 1977-04-05
DK136016C (ja) 1978-01-02
US3803115A (en) 1974-04-09
NO142381B (no) 1980-05-05
AT344881B (de) 1978-08-10
NL7306806A (ja) 1973-11-20

Similar Documents

Publication Publication Date Title
CH630804A5 (de) Verfahren zur verhinderung des abbaus der biochemischen aktivitaet von antihaemophilie-globulin.
DE69333928T2 (de) Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
DE2459291C3 (de) Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen
DE3750036T2 (de) Verfahren zur Depolymerisierung von Heparin zum Erhalten eines Heparins mit niedrigem Molekulargewicht und einer antithrombotischen Aktivität.
CH645537A5 (en) Antithrombin product and process for its production
DE2854381A1 (de) Verfahren zur gewinnung des antihaemophilen faktors viii aus blut, blutplasma oder blutplasma-fraktionen
DE2333883A1 (de) Verfahren zur herstellung von gereinigtem albumin durch anwendung einer thermokoagulation und das erhaltene gereinigte albumin
DE3150318C2 (de) "Verfahren zur Herstellung eines Polysaccharidderivats des Fibrinolysins"
DD298110A5 (de) Verfahren zur herstellung eines konzentrats des blutgerinnungsfaktor-viii-von-willebrand-faktor-komplexes aus gesamten plasma
EP0637451A1 (de) Virussichere Blutgerinnungsfaktor XIII-Präparation
DE2715832B2 (de) Verfahren zur Gewinnung von gereinigtem antihämophilem Globulin A (Faktor VIII)
DE3686390T2 (de) Verfahren zur herstellung vom antihaemophilfaktor (ahf) durch kaeltefaellung und zur verbesserung der loeslichkeit des hergestellten ahf-produktes.
DE1767285C3 (de) Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie
DE69326627T2 (de) Therapeutisches Mittel gegen drohenden Abortus
DE2703620C2 (de) Verfahren zur Herstellung eines Konzentrats des Antihämophiliefaktors
DE2605576C3 (de) Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten
DE2515666C3 (de) Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat
DE1442134B2 (de) In vivo antikoagulierend wirkendes und defibrinierendes Enzym
DE3019895A1 (de) Plasmaexpander
EP0127025A2 (de) Verfahren zur Herstellung eines Antihämophiliefaktor-Konzentrats
DE2262520C3 (de) Verfahren zur Herstellung eines lyophilisierten, lagerfähigen Konzentrats aus menschlichem Plasma
DE2653534C2 (de) Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
DE1617279A1 (de) Verfahren zur Herstellung pharmazeutischer Praeparate zur Verhinderung der Bildung von Blutgerinnseln
WO1986000015A1 (en) Cosmetic product for the treatment of the skin
DE2409650A1 (de) Waessrige haptoglobinloesungen, verfahren zu ihrer herstellung und arzneimittel

Legal Events

Date Code Title Description
PL Patent ceased